Development of TOF-PET using Cherenkov Radiation

Miyata, Manabu; Tomita, Hideki; Watanabe, K.; Kawarabayashi, Jun; Iguchi, Tetsuo

doi:10.3327/jnst.43.339

Cited by 6 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the use of Cerenkov radiation for scintillation counting has been described (8–11), the use of inherent light emission of radionuclides for in vivo imaging is a new concept (12). In a recent paper, Robertson et al were the first to characterize the use of Cerenkov radiation for the optical imaging of 18 F-labeled radiotracers in vivo (13).…”

Section: Introductionmentioning

confidence: 99%

Cerenkov Luminescence Imaging of Medical Isotopes

Ruggiero¹,

Holland²,

Lewis³

et al. 2010

J Nucl Med

281

264

View full text Add to dashboard Cite

The development of novel multimodality imaging agents and techniques represents the current frontier of research in the field of medical imaging science. However, the combination of nuclear tomography with optical techniques has yet to be established. Here, we report the use of the inherent optical emissions from the decay of radiopharmaceuticals for Cerenkov luminescence imaging (CLI) of tumors in vivo and correlate the results with those obtained from concordant immuno-PET studies. Methods: In vitro phantom studies were used to validate the visible light emission observed from a range of radionuclides including the positron emitters 18 F, 64 Cu, 89 Zr, and 124 I; b-emitter 131 I; and a-particle emitter 225 Ac for potential use in CLI. The novel radiolabeled monoclonal antibody 89 Zr-desferrioxamine B [DFO]-J591 for immuno-PET of prostate-specific membrane antigen (PSMA) expression was used to coregister and correlate the CLI signal observed with the immuno-PET images and biodistribution studies. Results: Phantom studies confirmed that Cerenkov radiation can be observed from a range of positron-, b-, and a-emitting radionuclides using standard optical imaging devices. The change in light emission intensity versus time was concordant with radionuclide decay and was also found to correlate linearly with both the activity concentration and the measured PET signal (percentage injected dose per gram). In vivo studies conducted in male severe combined immune deficient mice bearing PSMA-positive, subcutaneous LNCaP tumors demonstrated that tumor-specific uptake of 89 Zr-DFO-J591 could be visualized by both immuno-PET and CLI. Optical and immuno-PET signal intensities were found to increase over time from 24 to 96 h, and biodistribution studies were found to correlate well with both imaging modalities. Conclusion: These studies represent the first, to our knowledge, quantitative assessment of CLI for measuring radiotracer uptake in vivo. Many radionuclides common to both nuclear tomographic imaging and radiotherapy have the potential to be used in CLI. The value of CLI lies in its ability to image radionuclides that do not emit either positrons or g-rays and are, thus, unsuitable for use with current nuclear imaging modalities. Optical imaging of Cerenkov radiation emission shows excellent promise as a potential new imaging modality for the rapid, high-throughput screening of radiopharmaceuticals. In the field of medical imaging science, the concept of multimodality is providing the driving force for the development of the next generation of imaging techniques. The latest hybrid systems such as PET/CT and PET/MRI are transforming the clinical management of cancer patients by consolidating the noninvasive localization and temporal quantification of changes in tissue function and physiology available from PET, with the high-resolution anatomic maps provided by CT or MRI (1,2).In contrast to the immediate clinical impact of nuclear tomographic imaging, optical methods such fluorescencemediated tomography and bioluminescen...

show abstract

Section: Introductionmentioning

confidence: 99%

Cerenkov Luminescence Imaging of Medical Isotopes

Ruggiero¹,

Holland²,

Lewis³

et al. 2010

J Nucl Med

281

264

View full text Add to dashboard Cite

show abstract

“…Cerenkov luminescence is present in certain positron emitters (e.g. fluorine-18, copper-64, zirconium-89, iodine-124), beta emitters (iodine-131) as well as alpha emitters (actinium-225) [167,168]. To allow for the emission of Cerenkov radiation, the isotope should have a minimum beta energy yield of 263 keV [169].…”

Section: Multimodal Imagingmentioning

confidence: 99%

Radiopharmaceutical enhancement by drug delivery systems: A review

Kleynhans

Grobler

Ebenhan

et al. 2018

Journal of Controlled Release

View full text Add to dashboard Cite

show abstract

“…In recent years, the exploitation of prompt Cherenkov photons observed in some crystals and their potential benefits in improving detection timing abilities has sparked considerable scientific interest, as they provide the prospect of both high sensitivity and compelling timing properties when combined with BGO [ 20 ]–[ 29 ]. Cherenkov radiation is emitted when charged particles pass through a dielectric medium at speed greater than the phase velocity of light [ 30 ].…”

Section: Introductionmentioning

confidence: 99%

TOF-PET Image Reconstruction With Multiple Timing Kernels Applied on Cherenkov Radiation in BGO

Efthimiou

Kratochwil

Gundacker

et al. 2021

IEEE Trans. Radiat. Plasma Med. Sci.

View full text Add to dashboard Cite

Today Time-of-Flight (TOF), in PET scanners, assumes a single, well-defined timing resolution for all events. However, recent BGO–Cherenkov detectors, combining prompt Cherenkov emission and the typical BGO scintillation, can sort events into multiple timing kernels, best described by the Gaussian mixture models. The number of Cherenkov photons detected per event impacts directly the detector time resolution and signal rise time, which can later be used to improve the coincidence timing resolution. This work presents a simulation toolkit which applies multiple timing spreads on the coincident events and an image reconstruction that incorporates this information. A full cylindrical BGO–Cherenkov PET model was compared, in terms of contrast recovery and contrast-to-noise ratio, against an LYSO model with a time resolution of 213 ps. Two reconstruction approaches for the mixture kernels were tested: 1) mixture Gaussian and 2) decomposed simple Gaussian kernels. The decomposed model used the exact mixture component applied during the simulation. Images reconstructed using mixture kernels provided similar mean value and less noise than the decomposed. However, typically, more iterations were needed. Similarly, the LYSO model, with a single TOF kernel, converged faster than the BGO–Cherenkov with multiple kernels. The results indicate that the model complexity slows down convergence. However, due to the higher sensitivity, the contrast-to-noise ratio was 26.4% better for the BGO model.

show abstract

Development of TOF-PET using Cherenkov Radiation

Cited by 6 publications

References 5 publications

Cerenkov Luminescence Imaging of Medical Isotopes

Cerenkov Luminescence Imaging of Medical Isotopes

Radiopharmaceutical enhancement by drug delivery systems: A review

TOF-PET Image Reconstruction With Multiple Timing Kernels Applied on Cherenkov Radiation in BGO

Contact Info

Product

Resources

About